Adlai Nortye Announces Executive Leadership Changes: New President and CFO Appointed

On April 1, 2026, Adlai Nortye Ltd. announced several key changes to its executive leadership team. Dr. Archie Tse has been appointed as the Company's President while continuing his current role as Head of Research and Development, a position he has held since March 2024. Dr. Tse brings extensive experience from previous leadership roles at CStone Pharmaceuticals, MSD, and Daiichi-Sankyo. Additionally, the Board appointed Dr. Ye as Chief Financial Officer. Dr. Ye, who has served as interim CFO since January 2025, will also remain responsible for business development and global commercialization strategy. These appointments follow the retirement of Dr. Kaiyang Tang from his position as President, effective April 1, 2026. Dr. Tang will remain with the company as a Corporate Strategy Professor to facilitate a smooth transition. The company stated that these management changes are not expected to impact ongoing operations, including finance and investor relations. All newly appointed officers have confirmed they have no material interests in transactions requiring disclosure or family relationships with other directors or executive officers.